395 related articles for article (PubMed ID: 23863832)
1. Overcoming preexisting humoral immunity to AAV using capsid decoys.
Mingozzi F; Anguela XM; Pavani G; Chen Y; Davidson RJ; Hui DJ; Yazicioglu M; Elkouby L; Hinderer CJ; Faella A; Howard C; Tai A; Podsakoff GM; Zhou S; Basner-Tschakarjan E; Wright JF; High KA
Sci Transl Med; 2013 Jul; 5(194):194ra92. PubMed ID: 23863832
[TBL] [Abstract][Full Text] [Related]
2. Mapping an Adeno-associated Virus 9-Specific Neutralizing Epitope To Develop Next-Generation Gene Delivery Vectors.
Giles AR; Govindasamy L; Somanathan S; Wilson JM
J Virol; 2018 Oct; 92(20):. PubMed ID: 30089698
[TBL] [Abstract][Full Text] [Related]
3. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.
Scallan CD; Jiang H; Liu T; Patarroyo-White S; Sommer JM; Zhou S; Couto LB; Pierce GF
Blood; 2006 Mar; 107(5):1810-7. PubMed ID: 16249376
[TBL] [Abstract][Full Text] [Related]
4. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates.
Kotterman MA; Yin L; Strazzeri JM; Flannery JG; Merigan WH; Schaffer DV
Gene Ther; 2015 Feb; 22(2):116-26. PubMed ID: 25503696
[TBL] [Abstract][Full Text] [Related]
5. Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles.
Li C; Diprimio N; Bowles DE; Hirsch ML; Monahan PE; Asokan A; Rabinowitz J; Agbandje-McKenna M; Samulski RJ
J Virol; 2012 Aug; 86(15):7752-9. PubMed ID: 22593151
[TBL] [Abstract][Full Text] [Related]
6. Screening for Neutralizing Antibodies Against Natural and Engineered AAV Capsids in Nonhuman Primate Retinas.
Day TP; Byrne LC; Flannery JG; Schaffer DV
Methods Mol Biol; 2018; 1715():239-249. PubMed ID: 29188518
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
[TBL] [Abstract][Full Text] [Related]
8. Bat adeno-associated viruses as gene therapy vectors with the potential to evade human neutralizing antibodies.
Li Y; Li J; Liu Y; Shi Z; Liu H; Wei Y; Yang L
Gene Ther; 2019 Jun; 26(6):264-276. PubMed ID: 31110296
[TBL] [Abstract][Full Text] [Related]
9. AAV-mediated delivery of optogenetic constructs to the macaque brain triggers humoral immune responses.
Mendoza SD; El-Shamayleh Y; Horwitz GD
J Neurophysiol; 2017 May; 117(5):2004-2013. PubMed ID: 28202570
[TBL] [Abstract][Full Text] [Related]
10. Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines.
Lin J; Calcedo R; Vandenberghe LH; Figueredo JM; Wilson JM
Hum Gene Ther; 2008 Jul; 19(7):663-9. PubMed ID: 18549307
[TBL] [Abstract][Full Text] [Related]
11. Characterization of naturally-occurring humoral immunity to AAV in sheep.
Tellez J; Van Vliet K; Tseng YS; Finn JD; Tschernia N; Almeida-Porada G; Arruda VR; Agbandje-McKenna M; Porada CD
PLoS One; 2013; 8(9):e75142. PubMed ID: 24086458
[TBL] [Abstract][Full Text] [Related]
12. Preexisting Neutralizing Antibodies to Adeno-Associated Virus Capsids in Large Animals Other Than Monkeys May Confound In Vivo Gene Therapy Studies.
Calcedo R; Franco J; Qin Q; Richardson DW; Mason JB; Boyd S; Wilson JM
Hum Gene Ther Methods; 2015 Jun; 26(3):103-5. PubMed ID: 26067568
[TBL] [Abstract][Full Text] [Related]
13. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure.
Moskalenko M; Chen L; van Roey M; Donahue BA; Snyder RO; McArthur JG; Patel SD
J Virol; 2000 Feb; 74(4):1761-6. PubMed ID: 10644347
[TBL] [Abstract][Full Text] [Related]
14. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential.
Li Q; Miller R; Han PY; Pang J; Dinculescu A; Chiodo V; Hauswirth WW
Mol Vis; 2008 Sep; 14():1760-9. PubMed ID: 18836574
[TBL] [Abstract][Full Text] [Related]
15. Coevolution of Adeno-associated Virus Capsid Antigenicity and Tropism through a Structure-Guided Approach.
Havlik LP; Simon KE; Smith JK; Klinc KA; Tse LV; Oh DK; Fanous MM; Meganck RM; Mietzsch M; Kleinschmidt J; Agbandje-McKenna M; Asokan A
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669336
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.
Leborgne C; Latournerie V; Boutin S; Desgue D; Quéré A; Pignot E; Collaud F; Charles S; Simon Sola M; Masat E; Jouen F; Boyer O; Masurier C; Mingozzi F; Veron P
Cell Immunol; 2019 Aug; 342():103780. PubMed ID: 29571923
[TBL] [Abstract][Full Text] [Related]
17. Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo.
Sen D; Gadkari RA; Sudha G; Gabriel N; Kumar YS; Selot R; Samuel R; Rajalingam S; Ramya V; Nair SC; Srinivasan N; Srivastava A; Jayandharan GR
Hum Gene Ther Methods; 2013 Apr; 24(2):104-16. PubMed ID: 23442071
[TBL] [Abstract][Full Text] [Related]
18. Vector decoys trick the immune response.
VandenDriessche T; Chuah MK
Sci Transl Med; 2013 Jul; 5(194):194fs28. PubMed ID: 23863831
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo.
Li C; Hirsch M; DiPrimio N; Asokan A; Goudy K; Tisch R; Samulski RJ
J Virol; 2009 Jul; 83(13):6817-24. PubMed ID: 19369348
[TBL] [Abstract][Full Text] [Related]
20. Slow AAV2 clearance from the brain of nonhuman primates and anti-capsid immune response.
Samaranch L; Hadaczek P; Kells AP; Bringas JR; Stockinger D; San Sebastian W; Macayan M; Samineni S; Pivirotto P; Forsayeth J; Bankiewicz KS
Gene Ther; 2016 Apr; 23(4):393-8. PubMed ID: 26510688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
